DiagnaMed Announces Appointment of New Director
TORONTO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health generative...
Brain
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
MRI results reinforce the clinical neurological improvements previously reportedMRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory...
Inside Information: Nexstim Plc’s change negotiations have been completed
Company Announcement, Helsinki, 8 February 2023 at 3 PM (EET) Inside Information: Nexstim Plc’s change negotiations have been completed Nexstim...
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Ulixacaltamide (PRAX-944) Phase 2b Essential1 study topline results for essential tremor expected in 1Q23; Praxis to enter quiet period following...
Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Topline Data Expected in 2Q 2023SEATTLE, Wash and VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,...
Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 1 Study of [18F]OP-801 for Use as Imaging Agent
– The study will evaluate the safety, tolerability and ability of OP-801 to cross the blood brain barrier and selectively...
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology...
Bioasis Announces AGM Results and Provides Update on Financial Position
NEW HAVEN, Conn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset...
Vyant Bio Commences a Cash Preservation Plan Including a Reduction in Force
Continuing to Explore Strategic Alternatives CHERRY HILL, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”)...
ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits
Glen Rock, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a...
Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound
Tel Aviv, Israel / Vancouver, Canada, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:...
BenchSci Announces Launch of ASCEND™ – a First-of-its-Kind ‘Map’ of All Disease Biology that Aims to Transform Pharmaceutical Research
The SaaS solution is powered by proprietary machine-learning technology that reads and interprets data like a PhD scientist BenchSci ASCEND...
DiagnaMed Holdings Provides Update for BRAIN AGE™ Development and Commercialization Milestones for 2023
Complete IRB-approved research study in Q2-2023 Commercialize BRAIN AGE™ in Q4-2023 TORONTO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings...
Publication Analyzes Clinical Efficacy of Deep TMS™ in Treating Different Brain Regions Associated with Major Depressive Disorder
Study Results Outline a Potential Path to More Personalized Medicine in Noninvasive Brain StimulationBURLINGTON, Mass. and JERUSALEM, Jan. 31, 2023...
Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)
IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the...
Medicenna to Present at the 2023 Guggenheim Oncology Conference
TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage...
Achieve Life Sciences Announces Granting of New Hire Inducement Award
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage...
Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders
PHILADELPHIA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)...
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial...
Medicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023
TORONTO and HOUSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA),...